Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments
Svenja Müller, Claudia Zeidler, Sonja Ständer
American Journal of Clinical Dermatology (2023) Vol. 25, Iss. 1, pp. 15-33
Open Access | Times Cited: 24

Showing 24 citing articles:

Update Vulvadermatologie – Diagnostik und Therapie
Christine Brägelmann, Linn Wölber, Laura Susok, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2025) Vol. 23, Iss. 1, pp. 65-88
Open Access
Effectiveness and Safety of Dupilumab for Prurigo Nodularis in China: A Multicentric and Observational Study
Zuotao Zhao, Xiaoting Song, Yuanyuan Shang, et al.
Allergy (2025)
Open Access
Worldwide prevalence of prurigo nodularis: A systematic review and meta‐analysis
Farzad Alinaghi, Mikkel Bak Jensen, Jesper Elberling, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Closed Access
WISIT vaccines based on IL-31-derived peptides as a novel therapeutic approach for chronic pruritic dermatoses
Sabine Schmidhuber, James Dickie, Mihály Cserepes, et al.
PLoS ONE (2025) Vol. 20, Iss. 2, pp. e0318293-e0318293
Open Access
Effective Treatment of Prurigo Nodularis With Oral Tofacitinib: A Case Report
Nikoo Mozafari
Clinical Case Reports (2025) Vol. 13, Iss. 3
Open Access
Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives
Lawrence F. Eichenfield, J. Z. Liu, Simran Marwaha, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 3, pp. 685-696
Open Access | Times Cited: 4
Beyond the classic players: Mas‐related G protein‐coupled receptor member X2 role in pruritus and skin diseases
Mukesh Kumar, Ye Gi Choi, Trevor K. Wong, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Open Access | Times Cited: 4
Pharmacological treatment in Idiopathic Pulmonary Fibrosis: currentissues and future perspectives
Carlo Vancheri, Enrico Sciacca, Giuseppe Muscato, et al.
Multidisciplinary Respiratory Medicine (2024) Vol. 19, Iss. Vol. 19 (2024)
Open Access | Times Cited: 2
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis
Sonja Ständer, Gil Yosipovitch, Franz J. Legat, et al.
JAMA Dermatology (2024)
Closed Access | Times Cited: 2
Nemolizumab: a new key player in the treatment of prurigo nodularis
Adam Reich
British Journal of Dermatology (2024) Vol. 191, Iss. 2, pp. 154-155
Closed Access | Times Cited: 1
Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics
Hwa Jung Yook, Ji Hyun Lee
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5164-5164
Open Access | Times Cited: 1
Association between atopic dermatitis and prurigo nodularis: a systematic review and meta‐analysis
Wei Li, Yunze Pi, Jiwei Xu
International Journal of Dermatology (2024)
Closed Access | Times Cited: 1
Update vulval dermatology – diagnostics and therapy
Christine Brägelmann, Linn Wölber, Laura Susok, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2024) Vol. 23, Iss. 1, pp. 65-86
Open Access | Times Cited: 1
Baricitinib for Prurigo Nodularis: A Pilot Study on Efficacy and Safety
Padcha Pongcharoen, C Tuchinda, Panlop Chakkavittumrong, et al.
Dermatologic Therapy (2024) Vol. 2024, pp. 1-6
Open Access
Targeted Biologic Therapies in Chronic Prurigo: The Evolving Landscape of Chronic Prurigo Treatment
Aleksandra Stefaniak, Jacek C. Szepietowski
Current Pharmaceutical Design (2024) Vol. 30, Iss. 23, pp. 1787-1790
Closed Access
Prurigo nodularis: the difference between knowing the path and walking the path
J.M. Carrascosa, M. Munera‐Campos
British Journal of Dermatology (2024) Vol. 191, Iss. 4, pp. 480-481
Closed Access
Dupilumab may break the “itch‐scratch cycle” in chronic prurigo and induce remission in a subset of patients
João Teixeira, João Soares, André Aparício‐Martins, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access
TRP channels in dermatology
Attila Oláh, Attila Gábor Szöllősi, Balázs I. Tóth
Elsevier eBooks (2024), pp. 365-385
Closed Access
Time is the answer: Dupilumab effectiveness in prurigo nodularis patients
Sara Pruneddu
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 10, pp. 1848-1849
Closed Access
Landscape of Prurigo Nodularis Clinical Trials
Caitlyn B. Dagenet, Carissa Saadi, Mary A. Phillips, et al.
JAAD reviews. (2024) Vol. 2, pp. 127-136
Open Access
Relieve the intense itch of chronic prurigo with old and new therapies
Caroline Fenton, Simon Fung
Drugs & Therapy Perspectives (2024) Vol. 40, Iss. 11, pp. 455-458
Closed Access
Prurigo chronica multiformis: Expert consensus of the Japanese Dermatological Association
Takahiro Satoh, Hiroyuki Murota, Yumi Aoyama, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 11
Closed Access
Therapeutic unresponsiveness of gabapentin and hydroxyzine combination in moderate-severe chronic prurigo nodularis of Hyde
Sasmita Mishra, Subhasree Madhual, Maitreyee Panda
Indian Journal of Skin Allergy (2024), pp. 1-3
Closed Access
Besser spät als nie! Klarheit für eine 114 Jahre alte Erkrankung
Sonja Ständer
Kompass Dermatologie (2023) Vol. 11, Iss. 4, pp. 197-199
Closed Access
Page 1

Scroll to top